What is Medpace Holdings, Inc.'s market cap?

Medpace Holdings, Inc. (MEDP) has a market capitalization of $13.1B and trades on NASDAQ.

What is Medpace Holdings, Inc.'s revenue and profitability?

Medpace Holdings, Inc. generated $2.7B in trailing twelve-month revenue with net income of $460.4M, representing a net margin of 17.2%, with free cash flow of $711.0M. These figures are based on the Q1 2026 filing.

Who are Medpace Holdings, Inc.'s competitors?

Medpace Holdings, Inc.'s key competitors include IQVIA Holdings Inc., Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., and others. These companies compete in similar markets and product categories.

What subsidiaries does Medpace Holdings, Inc. have?

Medpace Holdings, Inc.'s subsidiaries include Medpace, Inc..

Where is Medpace Holdings, Inc. headquartered?

Medpace Holdings, Inc. is headquartered in United States of America and employs approximately 5,800 people. It has been publicly traded since 2016.

Medpace Holdings, Inc.

MEDP

Medpace Holdings is a leading global clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services.

Market cap

$13.14B+50.4%

Revenue$2.7B+24.2%Net income$460.4M+10.6%Free cash flow$711.0M+31.4%EPS (diluted)$15.88+21.2%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 22, 2026

Revenue$706.6MBeat by $9.0M EPS$4.28Beat by $0.54

Read the full report

Next report

Jul 22, 2026 (in a month)

Revenue estimate$690.7M

EPS estimate$3.98

Financials

Q1 2026

Income statement

See full

Revenue$706.6M+26.5%

Operating income$141.5M+24.6%

Net income$123.9M+8.1%

EPS (diluted)$4.28+16.6%

Balance sheet

See full

Cash & equivalents$652.7M+47.9%

Total debt$146.1M-2.8%

Total equity$598.3M+0.8%

Total assets$2.1B+12.2%

Cash flow

See full

Operating cash flow$151.8M+20.6%

CapEx$6.8M-31.8%

Free cash flow$145.0M+25.1%

Valuation & ratios

Valuation

See full

Market cap$13.14B+46.8%

Enterprise value$12.64B+45.9%

P/E28.6×+7.0×

P/S4.9×+0.8×

Profitability

See full

Operating margin21%-0.1pp

Net margin17.2%-2.1pp

FCF margin26.5%+1.5pp

Returns & leverage

See full

Return on equity77.3%+11.4pp

Debt / equity0.2×0.0×

Current ratio0.8×+0.1×

Segments

By product

See full

Oncology$237.6M+60.5%

Metabolic$201.2M+18.0%

Other$93.3M-2.6%

Cardiology$80.2M+46.1%

Central Nervous System$56.3M-3.5%

By segment

See full

Reportable Segment$706.6M+26.5%

Competitors

By market cap

Thermo Fisher Scientific$172.66B

IQVIA$28.0B

Veeva Systems$24.9B

Labcorp Holdings$21.0B

Tenet Healthcare$14.9B

Medpace Holdings, Inc.$13.1B

BrightSpring Health Services, Inc.$13.0B

Icon$11.2B

By revenue growth

BrightSpring Health Services, Inc.+28.0%

Medpace Holdings, Inc.+24.2%

Veeva Systems+16.3%

Labcorp Holdings+7.3%

IQVIA+7.3%

Tenet Healthcare+4.5%

Thermo Fisher Scientific+2.4%

By net margin

Veeva Systems28.37%

Medpace Holdings, Inc.17.19%

Thermo Fisher Scientific15.19%

Tenet Healthcare12.36%

IQVIA8.33%

Labcorp Holdings6.66%

BrightSpring Health Services, Inc.2.27%

Profile

Medpace Holdings is a leading global clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services. The company specializes in accelerating the development of medical therapeutics through a disciplined, full-service operating model that spans the entire clinical trial spectrum from Phase I to Phase IV.

Competitive position

A leading CRO known for a disciplined full-service model specifically tailored to small and mid-sized biopharmaceutical clients.

GeographiesGlobal, North America, Europe, Asia-Pacific

Customer segmentsSmall and Mid-sized Biopharma, Medical Device Manufacturers

Business modelProfessional Services, Outsourced Research and Development

SuppliersSpecialized medical equipment manufacturers, Software providers for clinical trial management, Laboratory supply companies

CustomersBiotechnology companies, Pharmaceutical corporations, Medical device developers

CountryUnited States of America

Listed2016

Employees5.8K

CEOAugust James Troendle

SectorHealthcare

IndustryMedical - Diagnostics & Research

Websitemedpace.com

FilingsSEC EDGAR

Ask your AI about Medpace Holdings, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Medpace Holdings, Inc.'s market cap?: Medpace Holdings, Inc. (MEDP) has a market capitalization of $13.1B and trades on NASDAQ.
What is Medpace Holdings, Inc.'s revenue and profitability?: Medpace Holdings, Inc. generated $2.7B in trailing twelve-month revenue with net income of $460.4M, representing a net margin of 17.2%, with free cash flow of $711.0M. These figures are based on the Q1 2026 filing.
Who are Medpace Holdings, Inc.'s competitors?: Medpace Holdings, Inc.'s key competitors include IQVIA Holdings Inc., Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., and others. These companies compete in similar markets and product categories.
What subsidiaries does Medpace Holdings, Inc. have?: Medpace Holdings, Inc.'s subsidiaries include Medpace, Inc..
Where is Medpace Holdings, Inc. headquartered?: Medpace Holdings, Inc. is headquartered in United States of America and employs approximately 5,800 people. It has been publicly traded since 2016.